This article positions the mechanism, route of administration, regulatory status, and study data on a purely scientific basis, without framing either approach as a replacement for the other
While encouraging, this is generally not as dramatic or rapid as whats seen with GLP-1 agonists like Ozempic
Although most surgeons will not hesitate to excise these lesions completely, scientific evidence to support such approach is lacking
It does not present one as clearly better than the other
I have spent more than three decades in a company that encouraged scientific discoveries in several diseases, including diabetes and obesity, and progressed them at a time when few companies believed in medical treatment for obesity, or indeed in GLP-1